Top-News
Biotechnologie Israel

BiondVax Pharmaceuticals Ltd ADR News

Aktie
WKN:  A3DZ0C ISIN:  US09073Q2049 US-Symbol:  SCNI
0,396 €
-0,004 €
-1,00%
16.05.24 10:54:04
Handeln Depot/Watchlist
Aktienanzahl *
4,35 Mio.
Marktkapitalisierung *
1,76 Mio. €
Streubesitz
-
Faktor
0.025
Originalaktie
IL0011052045
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 08.03.2024

BiondVax Pharmaceuticals Ltd ADR News

21.11.22 - PR Newswire
BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco
BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco PR Newswire
03.11.22 - PR Newswire
BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference
BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference PR Newswire
02.11.22 - PR Newswire
BiondVax provides plan to address Nasdaq compliance
BiondVax provides plan to address Nasdaq compliance PR Newswire
11.10.22 - PR Newswire
BiondVax to present at LD Micro Investor Conference in Los Angeles
BiondVax to present at LD Micro Investor Conference in Los Angeles PR Newswire
30.09.22 - PR Newswire
BiondVax announces financial plans to support its ongoing NanoAb pipeline development
BiondVax announces financial plans to support its ongoing NanoAb pipeline development PR Newswire
20.09.22 - PR Newswire
BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19
BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic ...
08.09.22 - PR Newswire
BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference
BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference PR Newswire
25.08.22 - PR Newswire
BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update
BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update PR Newswire
10.08.22 - PR Newswire
BiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategy
BiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategy PR ...
07.06.22 - PR Newswire
BiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trial
BiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-​in-human Phase 1/2a safety and efficacy ...
01.06.22 - PR Newswire
BiondVax Announces First Quarter 2022 Financial Results and Provides Business Update
BiondVax Announces First Quarter 2022 Financial Results and Provides Business Update PR Newswire
19.05.22 - PR Newswire
BiondVax to Present at H.C. Wainwright Global Investment Conference
BiondVax to Present at H.C. Wainwright Global Investment Conference PR Newswire
12.05.22 - PR Newswire
BiondVax Provides Update at Biomed Israel Conference and Announces Significant Progress in its Nanosized Antibodies Program
BiondVax Provides Update at Biomed Israel Conference and Announces Significant Progress in its Nanosized Antibodies Program PR Newswire
09.05.22 - PR Newswire
BiondVax to Present at this week's Biomed Israel Conference
BiondVax to Present at this week's Biomed Israel Conference PR Newswire
05.04.22 - PR Newswire
BiondVax to host a Hebrew-language analyst and investor webinar on April 6th
BiondVax to host a Hebrew-​language analyst and investor webinar on April 6th PR Newswire
31.03.22 - PR Newswire
BiondVax to host analyst and investor webinar on April 4th
BiondVax to host analyst and investor webinar on April 4th PR Newswire
28.03.22 - PR Newswire
BiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
BiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update PR Newswire
24.03.22 - PR Newswire
Thinking about buying stock in Nikola Corp, D-Market Electronic Services, Biondvax Pharmaceuticals, Trip.com, or Spectrum Pharmaceuticals?
Thinking about buying stock in Nikola Corp, D-Market Electronic Services, Biondvax Pharmaceuticals, Trip.com, or Spectrum Pharmaceuticals? PR Newswire
24.03.22 - PR Newswire
BiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapies
BiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapies - Broad collaboration with Max Planck ...
14.03.22 - PR Newswire
European Investment Bank Agrees in Principle to Extend the Maturity of its Loan until December 2027 with Additional Terms that Provide Continued Long-Term Support for BiondVax's New Strategy
European Investment Bank Agrees in Principle to Extend the Maturity of its Loan until December 2027 with Additional Terms that Provide Continued Long-Term Support for ...

Newssuche

Videos

newspaper
14.05.24 -16,04%
Technical Trading: DAX dienstags Long
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »